TMX Newsfile·2026-01-08 16:44Core Viewpoint - The law firm Brodsky & Smith is investigating potential claims against the Board of Directors of Ventyx Biosciences, Inc. for possible breaches of fiduciary duty related to the sale of the company to Eli Lilly and Company for $14.00 per share, totaling approximately $1.2 billion in equity value [1][2]. Group 1 - The investigation focuses on whether the Ventyx Board failed to conduct a fair process in the sale, particularly regarding the fairness of the deal consideration for shareholders [2]. - The sale price of $14.00 per share represents an aggregate equity value of about $1.2 billion [1]. Group 2 - Brodsky & Smith is a litigation law firm with a strong track record in representing shareholders in securities and class action lawsuits, having recovered millions for clients [3]. - The firm has been appointed as lead counsel in various class actions by numerous courts across the country [3].